In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Encore Pharmaceuticals Inc.

Latest From Encore Pharmaceuticals Inc.

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Deals M & A

Best of the Blog: IN VIVO, June 2008

In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite posts that didn't make it into stories covered elsewhere in this month's magazine: Changing of the Change Agents: Exit Wyeth's Ruffolo, Enter Orbimed's Dolsten; Cimzia Launch: Nothing Simple About It; Lundbeck Thanks Myriad For the Memories; Takeda's Millions Buy a Lot of Beer.

Deal Statistics Quarterly, Q2 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Encore Pharmaceuticals Inc.
  • Senior Management
  • Barbara E Loughman, PhD, COO
    William Wechter, PhD, Chmn. & CSO
  • Contact Info
  • Encore Pharmaceuticals Inc.
    Phone: (909) 558-4903
    Loma Linda Medical Center
    Rm. 1512
    Loma Linda, CA 92350